依达拉奉注射液治疗急性缺血性脑卒中患者时间窗的临床研究

目的：观察依达拉奉注射液治疗急性缺血性脑卒中患者疗效及其与时间窗的关系。方法将120例急性缺血性脑卒中患者随机分成试验组和对照组，对照组仅给予常规治疗，试验组在常规治疗基础上予依达拉奉注射液治疗，2次/d，连续治疗14 d为1个疗程。分别在患者入组前、治疗后3个月采用美国国立卫生研究院卒中量表（NIHSS）进行评估，并于治疗后24 h、48 h、72 h行头颅CT观察并记录梗死面积的变化。结果试验组NIHSS疗效总有效率为83.33%，明显优于对照组的70.00%（χ2=5.70，P＜0.05）。两组治疗后3个月NIHSS评分均比治疗前明显下降（t分别=7.61、2.98，P均＜0.05）。两组治疗后3个月NIHSS评分比较，差异有统计学意义（t=5.27，P＜0.05）。试验组治疗后24 h、48 h、72 h头颅CT梗死面积与对照组同时点比较均有缩小，差异有统计学意义（t分别=4.33、3.67、4.18，P均＜0.05），且试验组治疗后72 h与治疗前的CT梗死面积差值与对照组比较，差异有统计学意义（t=3.20， P＜0.05）。将试验组按照发病时间分为发病24 h、48 h、72 h三组，三组治疗前NIHSS评分、CT梗死面积比较，差异均无统计学意义（F分别=3.05、2.98，P均＞0.05）；三组治疗后NIHSS评分、CT梗死面积比较，差异均具有统计学意义（F分别=4.92、4.01，P均＜0.05）。三组治疗后NIHSS评分、CT梗死面积两两比较，差异均有统计学意义（t分别=3.24、4.74、4.56；3.64、4.71、4.28，P均＜0.05）。结论尽早使用依达拉奉治疗急性缺血性脑卒中患者，可明显改善患者的神经功能缺损。

Clinical research of time window about edaravone treating patients with acute ischemic stroke

Objective To observe the clinical effect of edaravone for treating patients with acute ischemic stroke and to explore its association with time windows. Methods A total of 120 patients with acute ischemic stroke were randomly divided into treatment group and control group. The control group was received basic treatment. The treatment group was given edaravone injection that two times per day for fourteen days on the basis of basic treatment. All patients were given NIHSS scale evaluation at pretreatment and 3 months and underwent head CT at 24 hours, 48 hours and 72 hours after treatment. The infarct sizes were compared. Results The total effective rate of treatment group was 83.33% which was significantly higher than that of the control group （χ2=5.70,P〉0.05）. The NIHSS scores of two groups at 3 months after treatment were significantly lower than pre-treatment （t=7.61,2.98,P〉0.05）. There was statistically significant difference of NIHSS score at 3 months after treatment between two groups （t=5.27,P〉0.05）. The head CT infarct sizes at 24 hours, 48 hours and 72 hours after treatment of treatment group were significantly smaller than control group （t=4.33,3.67,4.18, P〉0.05）. The difference between pre-treatment and 72 hours after treatment of treatment group was significantly greater than that of the control group（t=3.20,P〉0.05）. The treatment group was divided into 24 hours group, 48 hours group and 72 hours group according to the onset time. The differences of NIHSS scores and infarct sizes before treatment among 24 hours group, 48 hours group and 72 hours group were not statistically significant （F=3.05, 2.98,P〈0.05） while they were significantly different after treatment（F=4.92, 4.01,P〉0.05） . The differences of NHISS scores and infarct sizes were sta-tistical significance when three groups compared with each other （t=3.24, 4.74, 4.56,3.64,4.71,4.28,P〉0.05）. Conclu-sion Early using of edaravone in patients with acute ischemic stroke can improve the neurological function defect of patients.